Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qingzhixiaoyan decoction is a Traditional Chinese Medicine (TCM) herbal formula developed by Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine. It is primarily indicated for the management of hyperlipidemia and metabolic disturbances in breast cancer patients, particularly those undergoing endocrine therapy with aromatase inhibitors (AIs). The formula is designed to address the 'phlegm-stasis' and 'heat-toxicity' patterns identified in TCM theory as contributors to metabolic dysfunction and tumor progression. Mechanistically, research suggests that the decoction regulates lipid metabolism and exerts anti-inflammatory effects by modulating the PI3K/Akt/mTOR signaling pathway and influencing the expression of key metabolic regulators such as PPAR-gamma and SREBP-1. Clinical evidence indicates its potential to improve lipid profiles and mitigate the cardiovascular side effects associated with long-term AI treatment.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qingzhixiaoyan decoction.